Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.73 |
| ▸ | HTT | P42858 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | LTA4H | P09960 | 1/20 | 0.60 |
| ▸ | MCHR1 | Q99705 | 5/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.52 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12781826 | 0.92 | ALDH1A1 (0.67) | SMN1; SMN2HTTALDH1A1LMNAL3MBTL1 | |
| SCHEMBL10223352 | 0.88 | SMN1; SMN2 (0.57) | SMN1; SMN2HTTALDH1A1LMNAL3MBTL1 | |
| SCHEMBL12781820 | 0.86 | ALDH1A1 (0.67) | SMN1; SMN2HTTALDH1A1LMNAL3MBTL1 | |
| SCHEMBL19731505 | 0.85 | HTT (0.60) | SMN1; SMN2HTTALDH1A1LMNAL3MBTL1 | |
| SCHEMBL9627983 | 0.84 | SMN1; SMN2 (1.00) | SMN1; SMN2HTTALDH1A1LMNAL3MBTL1 | |
| SCHEMBL12704026 | 0.83 | SMN1; SMN2 (0.69) | SMN1; SMN2HTTALDH1A1LMNAL3MBTL1 | |
| SCHEMBL13239766 | 0.83 | SMN1; SMN2 (0.69) | SMN1; SMN2HTTALDH1A1LMNAL3MBTL1 | |
| Hydrochloric Acid SCHEMBL10546975 | 0.83 | SMN1; SMN2 (0.97) | SMN1; SMN2HTTALDH1A1LMNAL3MBTL1 | |
| SCHEMBL20374404 | 0.83 | SMN1; SMN2 (0.73) | SMN1; SMN2HTTALDH1A1LMNAL3MBTL1 | |
| SCHEMBL27317490 | 0.83 | SMN1; SMN2 (0.57) | SMN1; SMN2HTTALDH1A1LMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586751-B2 | Nicotinamide compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-11-19 | — | — | US | disclosed |
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MEYERS SQUIBB COMPANY | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | NADK, BTK, NAMPT | SMN1; SMN2 2328/4885HTT 3854/4885ALDH1A1 2193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.